Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review

Jason D. Merker, Geoffrey R. Oxnard, Carolyn Compton, Maximilian Diehn, Patricia Hurley, Alexander J. Lazar, Neal Lindeman, Christina M. Lockwood, Alex J. Rai, Richard L. Schilsky, Apostolia M. Tsimberidou, Patricia Vasalos, Brooke L. Billman, Thomas K. Oliver, Suanna S. Bruinooge, Daniel F. Hayes, Nicholas C. Turner

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Purpose. - Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology and the College of American Pathologists summarizes current information about clinical ctDNA assays and provides a framework for future research. Methods. - An Expert Panel conducted a literature review on the use of ctDNA assays for solid tumors, including preanalytical variables, analytical validity, interpretation and reporting, and clinical validity and utility. Results. - The literature search identified 1338 references. Of those, 390, plus 31 references supplied by the Expert Panel, were selected for full-text review. There were 77 articles selected for inclusion. Conclusions. - The evidence indicates that testing for ctDNA is optimally performed on plasma collected in cell stabilization or EDTA tubes, with EDTA tubes processed within 6 hours of collection. Some ctDNA assays have demonstrated clinical validity and utility with certain types of advanced cancer; however, there is insufficient evidence of clinical validity and utility for the majority of ctDNA assays in advanced cancer. Evidence shows discordance between the results of ctDNA assays and genotyping tumor specimens, and supports tumor tissue genotyping to confirm undetected results from ctDNA tests. There is no evidence of clinical utility and little evidence of clinical validity of ctDNA assays in early-stage cancer, treatment monitoring, or residual disease detection. There is no evidence of clinical validity or clinical utility to suggest that ctDNA assays are useful for cancer screening, outside of a clinical trial. Given the rapid pace of research, reevaluation of the literature will shortly be required, along with the development of tools and guidance for clinical practice.

Original languageEnglish (US)
Pages (from-to)1242-1253
Number of pages12
JournalArchives of Pathology and Laboratory Medicine
Volume142
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Medical Oncology
DNA
Neoplasms
Pathologists
Edetic Acid
Early Detection of Cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Circulating tumor DNA analysis in patients with cancer : American society of clinical oncology and college of American pathologists joint review. / Merker, Jason D.; Oxnard, Geoffrey R.; Compton, Carolyn; Diehn, Maximilian; Hurley, Patricia; Lazar, Alexander J.; Lindeman, Neal; Lockwood, Christina M.; Rai, Alex J.; Schilsky, Richard L.; Tsimberidou, Apostolia M.; Vasalos, Patricia; Billman, Brooke L.; Oliver, Thomas K.; Bruinooge, Suanna S.; Hayes, Daniel F.; Turner, Nicholas C.

In: Archives of Pathology and Laboratory Medicine, Vol. 142, No. 10, 01.10.2018, p. 1242-1253.

Research output: Contribution to journalReview article

Merker, JD, Oxnard, GR, Compton, C, Diehn, M, Hurley, P, Lazar, AJ, Lindeman, N, Lockwood, CM, Rai, AJ, Schilsky, RL, Tsimberidou, AM, Vasalos, P, Billman, BL, Oliver, TK, Bruinooge, SS, Hayes, DF & Turner, NC 2018, 'Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review', Archives of Pathology and Laboratory Medicine, vol. 142, no. 10, pp. 1242-1253. https://doi.org/10.5858/arpa.2018-0901-SA
Merker, Jason D. ; Oxnard, Geoffrey R. ; Compton, Carolyn ; Diehn, Maximilian ; Hurley, Patricia ; Lazar, Alexander J. ; Lindeman, Neal ; Lockwood, Christina M. ; Rai, Alex J. ; Schilsky, Richard L. ; Tsimberidou, Apostolia M. ; Vasalos, Patricia ; Billman, Brooke L. ; Oliver, Thomas K. ; Bruinooge, Suanna S. ; Hayes, Daniel F. ; Turner, Nicholas C. / Circulating tumor DNA analysis in patients with cancer : American society of clinical oncology and college of American pathologists joint review. In: Archives of Pathology and Laboratory Medicine. 2018 ; Vol. 142, No. 10. pp. 1242-1253.
@article{4347588454ff4156b80b39bc43f70789,
title = "Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review",
abstract = "Purpose. - Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology and the College of American Pathologists summarizes current information about clinical ctDNA assays and provides a framework for future research. Methods. - An Expert Panel conducted a literature review on the use of ctDNA assays for solid tumors, including preanalytical variables, analytical validity, interpretation and reporting, and clinical validity and utility. Results. - The literature search identified 1338 references. Of those, 390, plus 31 references supplied by the Expert Panel, were selected for full-text review. There were 77 articles selected for inclusion. Conclusions. - The evidence indicates that testing for ctDNA is optimally performed on plasma collected in cell stabilization or EDTA tubes, with EDTA tubes processed within 6 hours of collection. Some ctDNA assays have demonstrated clinical validity and utility with certain types of advanced cancer; however, there is insufficient evidence of clinical validity and utility for the majority of ctDNA assays in advanced cancer. Evidence shows discordance between the results of ctDNA assays and genotyping tumor specimens, and supports tumor tissue genotyping to confirm undetected results from ctDNA tests. There is no evidence of clinical utility and little evidence of clinical validity of ctDNA assays in early-stage cancer, treatment monitoring, or residual disease detection. There is no evidence of clinical validity or clinical utility to suggest that ctDNA assays are useful for cancer screening, outside of a clinical trial. Given the rapid pace of research, reevaluation of the literature will shortly be required, along with the development of tools and guidance for clinical practice.",
author = "Merker, {Jason D.} and Oxnard, {Geoffrey R.} and Carolyn Compton and Maximilian Diehn and Patricia Hurley and Lazar, {Alexander J.} and Neal Lindeman and Lockwood, {Christina M.} and Rai, {Alex J.} and Schilsky, {Richard L.} and Tsimberidou, {Apostolia M.} and Patricia Vasalos and Billman, {Brooke L.} and Oliver, {Thomas K.} and Bruinooge, {Suanna S.} and Hayes, {Daniel F.} and Turner, {Nicholas C.}",
year = "2018",
month = "10",
day = "1",
doi = "10.5858/arpa.2018-0901-SA",
language = "English (US)",
volume = "142",
pages = "1242--1253",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "10",

}

TY - JOUR

T1 - Circulating tumor DNA analysis in patients with cancer

T2 - American society of clinical oncology and college of American pathologists joint review

AU - Merker, Jason D.

AU - Oxnard, Geoffrey R.

AU - Compton, Carolyn

AU - Diehn, Maximilian

AU - Hurley, Patricia

AU - Lazar, Alexander J.

AU - Lindeman, Neal

AU - Lockwood, Christina M.

AU - Rai, Alex J.

AU - Schilsky, Richard L.

AU - Tsimberidou, Apostolia M.

AU - Vasalos, Patricia

AU - Billman, Brooke L.

AU - Oliver, Thomas K.

AU - Bruinooge, Suanna S.

AU - Hayes, Daniel F.

AU - Turner, Nicholas C.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Purpose. - Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology and the College of American Pathologists summarizes current information about clinical ctDNA assays and provides a framework for future research. Methods. - An Expert Panel conducted a literature review on the use of ctDNA assays for solid tumors, including preanalytical variables, analytical validity, interpretation and reporting, and clinical validity and utility. Results. - The literature search identified 1338 references. Of those, 390, plus 31 references supplied by the Expert Panel, were selected for full-text review. There were 77 articles selected for inclusion. Conclusions. - The evidence indicates that testing for ctDNA is optimally performed on plasma collected in cell stabilization or EDTA tubes, with EDTA tubes processed within 6 hours of collection. Some ctDNA assays have demonstrated clinical validity and utility with certain types of advanced cancer; however, there is insufficient evidence of clinical validity and utility for the majority of ctDNA assays in advanced cancer. Evidence shows discordance between the results of ctDNA assays and genotyping tumor specimens, and supports tumor tissue genotyping to confirm undetected results from ctDNA tests. There is no evidence of clinical utility and little evidence of clinical validity of ctDNA assays in early-stage cancer, treatment monitoring, or residual disease detection. There is no evidence of clinical validity or clinical utility to suggest that ctDNA assays are useful for cancer screening, outside of a clinical trial. Given the rapid pace of research, reevaluation of the literature will shortly be required, along with the development of tools and guidance for clinical practice.

AB - Purpose. - Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology and the College of American Pathologists summarizes current information about clinical ctDNA assays and provides a framework for future research. Methods. - An Expert Panel conducted a literature review on the use of ctDNA assays for solid tumors, including preanalytical variables, analytical validity, interpretation and reporting, and clinical validity and utility. Results. - The literature search identified 1338 references. Of those, 390, plus 31 references supplied by the Expert Panel, were selected for full-text review. There were 77 articles selected for inclusion. Conclusions. - The evidence indicates that testing for ctDNA is optimally performed on plasma collected in cell stabilization or EDTA tubes, with EDTA tubes processed within 6 hours of collection. Some ctDNA assays have demonstrated clinical validity and utility with certain types of advanced cancer; however, there is insufficient evidence of clinical validity and utility for the majority of ctDNA assays in advanced cancer. Evidence shows discordance between the results of ctDNA assays and genotyping tumor specimens, and supports tumor tissue genotyping to confirm undetected results from ctDNA tests. There is no evidence of clinical utility and little evidence of clinical validity of ctDNA assays in early-stage cancer, treatment monitoring, or residual disease detection. There is no evidence of clinical validity or clinical utility to suggest that ctDNA assays are useful for cancer screening, outside of a clinical trial. Given the rapid pace of research, reevaluation of the literature will shortly be required, along with the development of tools and guidance for clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85050872574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050872574&partnerID=8YFLogxK

U2 - 10.5858/arpa.2018-0901-SA

DO - 10.5858/arpa.2018-0901-SA

M3 - Review article

C2 - 29504834

AN - SCOPUS:85050872574

VL - 142

SP - 1242

EP - 1253

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 10

ER -